PMA supplement
P970029 S024: CARDIOGENESIS TRANSMYOCARDIAL LASER REVASCULARIZATION SYSTEM
FDA PMA supplement · Real-Time Process · Cryolife, Inc.
Key facts
| Original PMA | P970029 |
|---|---|
| Supplement number | S024 |
| Supplement type | Real-Time Process |
| Reason for the supplement | Change Design/Components/Specifications/Material |
| Trade name | CARDIOGENESIS TRANSMYOCARDIAL LASER REVASCULARIZATION SYSTEM |
| Generic name | SYSTEM, LASER, TRANSMYOCARDIAL REVASCULARIZATION |
| Applicant | Cryolife, Inc. |
| Product code | MNO |
| Received date | Jan 29, 2013 |
| Decision date | May 31, 2013 |
At a glance
- No Expedited review granted
- No Approval order on file
- No Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: